Education
About Us
Working with TipRanks
Follow Us
Cns Pharmaceuticals, Inc. (CNSP)
:CNSP
CNSP Stock Chart & Stats
$9.20
<$0.01(4.42%)
At close: 4:00 PM EST
$9.20
<$0.01(4.42%)
Day’s Range― - ―
52-Week Range$4.93 - $114.00
Previous CloseN/A
Volume19.26M
Average Volume (3M)24.82K
Market Cap
$3.79M
Enterprise ValueN/A
Total Cash (Recent Filing)$12.13M
Total Debt (Recent Filing)$121.77K
Price to Earnings (P/E)―
Beta2.67
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding574,580
10 Day Avg. Volume22,003
30 Day Avg. Volume24,819
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.71
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$20.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTPI-287 demonstrated an overall response rate of 60% in a Phase 1 trial for rGBM, with a 96% disease control rate, indicating promising efficacy.
Drug DevelopmentCNS Pharmaceuticals is upgrading shares to Buy due to the pivot to its oncology asset TPI-287, which is in development for recurrent glioblastoma (rGBM).
Bears Say
Analyst DowngradeIt is unclear what the path forward is for Berubicin, and given that Berubicin was the main driver of our thesis, analysts are removing it from their model and downgrading CNSP shares to Hold, from Buy.
Trial FailureCNS Pharmaceuticals shares are at an all-time low due to the Berubicin trial missing its primary endpoint in March.
CNS Pharmaceuticals News
CNSP FAQ
What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?
Cns Pharmaceuticals, Inc. lowest stock price was $4.93 and its highest was $114.00 in the past 12 months.
What is Cns Pharmaceuticals, Inc.’s market cap?
Cns Pharmaceuticals, Inc.’s market cap is $3.79M.
When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?
Cns Pharmaceuticals, Inc.’s upcoming earnings report date is May 18, 2026 which is in 184 days.
How were Cns Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Cns Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Cns Pharmaceuticals, Inc. pay dividends?
Cns Pharmaceuticals, Inc. does not currently pay dividends.
What is Cns Pharmaceuticals, Inc.’s EPS estimate?
Cns Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cns Pharmaceuticals, Inc. have?
Cns Pharmaceuticals, Inc. has 574,580 shares outstanding.
What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in CNSP
Company Description
Cns Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing novel treatments for brain tumors. The company is particularly dedicated to advancing its lead drug candidate, Berubicin, which is being investigated for the treatment of glioblastoma multiforme, a highly aggressive form of brain cancer. CNS Pharmaceuticals operates in the biopharmaceutical sector and is committed to addressing unmet medical needs through innovative research and development.
CNSP Stock 12 Month Forecast
Average Price Target
$20.00
▲(117.39% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Oragenics
―
InMed Pharmaceuticals
―
GRI Bio
―
Ownership Overview
10.50%
Insiders
<0.01% Mutual Funds
0.21% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---